ENOXACIN

US Previously Marketed

First approved in 1991

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H17FN4O3
Molecular Weight	320.3195
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCn1cc(c(=O)c2cc(c(nc21)N3CCNCC3)F)C(=O)O

InChI

InChIKey=IDYZIJYBMGIQMJ-UHFFFAOYSA-N

InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)

HIDE SMILES / InChI

Molecular Formula	C15H17FN4O3
Molecular Weight	320.3195
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6226242 | https://www.ncbi.nlm.nih.gov/pubmed/8429114 | https://www.ncbi.nlm.nih.gov/pubmed/8494374

Enoxacin is an oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract infections and gonorrhea. Enoxacin is bactericidal drugs, eradicating bacteria by interfering with DNA replication. Like other fluoroquinolones, enoxacin functions by inhibiting bacterial DNA gyrase and topoisomerase IV. The inhibition of these enzymes prevents bacterial DNA replication, transcription, repair and recombination. Enoxacin is active against many Gram-positive bacteria. After oral administration enoxacin is rapidly and well absorbed from the gastrointestinal tract. The antibiotic is widely distributed throughout the body and in the different biological tissues. Tissue concentrations often exceed serum concentrations. The binding of enoxacin to serum proteins is 35 to 40%. The serum elimination half-life, in subjects with normal renal function, is approximately 6 hours. Approximately 60% of an orally administered dose is excreted in the urine as unchanged drug within 24 hours. Enoxacin, like other fluoroquinolones, is known to trigger seizures or lower the seizure threshold. The compound should not be administered to patients with epilepsy or a personal history of previous convulsive attacks as may promote the onset of these disorders.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Topoisomerase IV 56 Target ID: CHEMBL2363077 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18813225	Inhibitor 7728
Bacterial DNA gyrase 59 Target ID: CHEMBL2311224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9341164	Inhibitor 7728

Conditions

Condition	Modality	Highest Phase	Product
Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. 3 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8043	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 6.9413759E11
Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis, or Staphylococcus saprophyticus 3 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8043	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 6.9413759E11
Complicated urinary tract infections 11 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8043	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 6.9413759E11

C_max

Value	Dose	Analyte	Population
7.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.58 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.02 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.83 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
25.75 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
29.08 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.67 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.35 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Doses

Dose	Population	Adverse events
600 mg single, oral Highest studied dose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	unhealthy, 41.9 years n = 79 Health Status: unhealthy Condition: cystitis Age Group: 41.9 years Sex: M+F Population Size: 79 Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	unhealthy, 43.8 years n = 75 Health Status: unhealthy Condition: cystitis Age Group: 43.8 years Sex: M+F Population Size: 75 Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/
600 mg 3 times / day multiple, oral (max) Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult n = 20060 Health Status: unhealthy Condition: Gram-negative urinary tract pathogens Age Group: adult Sex: M+F Population Size: 20060 Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	Other AEs: Gastrointestinal disorders, Epidermal and dermal conditions... Other AEs: Gastrointestinal disorders (1.3%) Epidermal and dermal conditions (0.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/

AEs

AE	Significance	Dose	Population
Epidermal and dermal conditions	0.4%	600 mg 3 times / day multiple, oral (max) Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult n = 20060 Health Status: unhealthy Condition: Gram-negative urinary tract pathogens Age Group: adult Sex: M+F Population Size: 20060 Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/
Gastrointestinal disorders	1.3%	600 mg 3 times / day multiple, oral (max) Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult n = 20060 Health Status: unhealthy Condition: Gram-negative urinary tract pathogens Age Group: adult Sex: M+F Population Size: 20060 Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1383 P-gp 1330	MATE1 127 OATP1A2 57	CYP1A2 637 CYP2B1 23 CYP2B2 12 CYP2E1 117 CYP3A1 4 CYP3A2 6 CYP4A1 17 CYP1A1 98

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A1 192	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2B1 38	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2B2 13	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2E1 871	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP3A1 5	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP3A2 12	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP4A1 24	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
P-gp 1514	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/15543082/	no
CYP1A2 1532	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/8347124/;https://pubmed.ncbi.nlm.nih.gov/10096258/	yes [Inhibition 250 uM]	yes (co-administration study) Comment: enoxacin caused a 6-fold decrease in caffeine clearance Sources: https://pubmed.ncbi.nlm.nih.gov/8347124/;https://pubmed.ncbi.nlm.nih.gov/10096258/
CYP1A2 1532	inducer 1440 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
MATE1 127	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/19004926/	yes
OATP1A2 57	substrate 3113 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565919/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:157175	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:157175
ChemicalBook	CB2403021	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2403021
MolPort	MolPort-003-666-456	https://www.molport.com/shop/molecule-link/MolPort-003-666-456
Selleck Chemicals	Enoxacin(Penetrex)	http://www.selleckchem.com/products/Enoxacin(Penetrex).html
ZINC	ZINC000019594549	http://zinc15.docking.org/substances/ZINC000019594549
eMolecules	538022	https://www.emolecules.com/cgi-bin/more?vid=538022

PubMed

Title	Date	PubMed
Assessment of temafloxacin neurotoxicity in rodents.	1991 Dec 30	1662895
Hippocampus and frontal cortex are the potential mediatory sites for convulsions induced by new quinolones and non-steroidal anti-inflammatory drugs.	1991 Jun	1651287
Interaction of the new quinolone antibacterial agent levofloxacin with fenbufen in mice.	1992 Mar	1622442
[Effects of drugs on the convulsions induced by the combination of a new quinolone antimicrobial, enoxacin, and a nonsteroidal anti-inflammatory drug, fenbufen, in mice].	1992 Oct	1446880
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.	2001	11735605
A pharmacokinetic/pharmacodynamic approach to show that not all fluoroquinolones exhibit similar sensitivity toward the proconvulsant effect of biphenyl acetic acid in rats.	2001 Dec	11733465
Quinolones and false-positive urine screening for opiates by immunoassay technology.	2001 Dec 26	11754677
Selective separation and simultaneous determination of trace levels of five types of fluorinated quinolone drugs by thin-layer chromatography/fluorescence densitometry.	2001 May-Jun	11417631
Synthesis and antibacterial activity of some novel N-substituted piperazinyl-quinolones.	2001 Nov-Dec	11822230
Is more than one quinolone needed in clinical practice?	2001 Sep	11573860
Multiresidue determination of (fluoro)quinolone antibiotics in swine kidney using liquid chromatography-tandem mass spectrometry.	2002 Apr 5	12064523
Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus.	2002 Dec	12461001
The expanding role of fluoroquinolones.	2002 Jul 8	12113871
Possible gatifloxacin-induced fulminant hepatic failure.	2002 Jul-Aug	12086547
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].	2002 Jun	12199111
[Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent--in vitro and in vivo studies].	2002 Jun	12199110
[The history of the development and changes of quinolone antibacterial agents].	2003	15143768
[Surveillance on concurrent administration of quinolones and anti-inflammatory drugs in a community hospital].	2003 Aug	14567251
Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system.	2003 Feb	12696183
Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.	2003 Jan	12533275
Interference-free analysis using three-way fluorescence data and the parallel factor model. Determination of fluoroquinolone antibiotics in human serum.	2003 Jun 1	12948131
Enoxacin trihydrate.	2004 Apr	15071236
Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture.	2004 Apr-Jun	15244525
Validation of HPLC method for determination of six fluoroquinolones: cinoxacin, ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin.	2004 Dec	15909943
Effects of eight antibacterial agents on cell survival and expression of epithelial-cell- or cell-adhesion-related genes in human gingival epithelial cells.	2004 Feb	14687228
Sensitivity and spectrum of bacterial isolates in infectious otitis externa.	2004 Mar	15228846
Spectroscopic properties of various quinolone antibiotics in aqueous-organic solvent mixtures.	2004 Nov-Dec	15623343
Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux.	2004 Nov-Dec	15543082
A novel approach to estimate in vitro antibacterial potency of Chinese medicine using a concentration-killing curve method.	2005	16173540
Determination of fluoroquinolones in edible animal tissue samples by high performance liquid chromatography after solid phase extraction.	2005 Apr	15881086
Evaluation of phototoxic and photoallergic potentials of 13 compounds by different in vitro and in vivo methods.	2005 Apr 4	15792876
HPLC determination of enoxacin, ciprofloxacin, norfloxacin and ofloxacin with photoinduced fluorimetric (PIF) detection and multiemission scanning: application to urine and serum.	2005 Aug 5	16006203
Selective action of fluoroquinolones against intracellular amastigotes of Leishmania (Viannia) panamensis in vitro.	2005 Dec	16539034
Celecoxib does not induce convulsions nor does it affect GABAA receptor binding activity in the presence of new quinolones in mice.	2005 Jan 10	15659296
Induced and photoinduced DNA damage by quinolones: ciprofloxacin, ofloxacin and nalidixic acid determined by comet assay.	2005 Jul-Aug	15691228
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Direct determination of five fluoroquinolones in chicken whole blood and in veterinary drugs by HPLC.	2005 Mar	15792246
Antibacterial studies, DNA oxidative cleavage, and crystal structures of Cu(II) and Co(II) complexes with two quinolone family members, ciprofloxacin and enoxacin.	2005 Mar	15708788
Fluoroquinolone-resistant Campylobacter isolates from conventional and antibiotic-free chicken products.	2005 May	15866763
Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.	2005 May	15848290
Vibrational spectroscopic characterization of fluoroquinolones.	2005 May	15820884
Effect of fluoroquinolones on plasma glucose levels in fasted and glucose-loaded mice.	2006 Apr	16648952
Radiation-induced in vitro phototoxic potential of some fluoroquinolones.	2006 Jan	16455588
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity.	2006 Jan	16393267
Photophysics and photochemistry of nalidixic acid.	2006 Jan-Feb	16107187
A batch chemiluminescence determination of enoxacin using a tris-(1,10-phenanthroline)ruthenium(II)-cerium(IV) system.	2006 Jul	16794867
Quinolones for uncomplicated acute cystitis in women.	2006 Jul 19	16856014
[Study on interaction of caffeine and theophylline with bovine serum albumins].	2006 Mar	16830766
A new approach to quantitative NMR: fluoroquinolones analysis by evaluating the chemical shift displacements.	2006 Oct 11	16765011
Induction of keratinocyte apoptosis by photosensitizing chemicals plus UVA.	2007 Feb	17141480

Patents

Sample Use Guides

In Vivo Use Guide

Enoxacin should be taken at least one hour before or at least two hours after a meal. For treatment uncomplicated urethral or cervical gonorrhea: 400 mg single dose. For treatment uncomplicated urinary tract infections 200 mg q12h for 7 days. For treatment complicated urinary tract infections: 400 mg q12h for 14 days. Dosage should be adjusted in patients with a creatinine clearance value of 30 mL/min/1.73 m 2 or less.

Route of Administration: Oral

In Vitro Use Guide

The in vitro antibacterial activity of AT-2266 (Enoxacin ) was tested by the determination of minimal bactericidal concentrations (MBCs) and the reduction of viable cells during exposure to the drug for 24 h. MIC90s of AT-2266 for P. aeruginosa resistant to gentamicin and Enterobacteriaceae resistant to nalidixic acid were 3.13 and 12.5 mkg/ml, respectively

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:51:50 UTC 2021` Edited by `admin` on `Fri Jun 25 21:51:50 UTC 2021`
Record UNII	325OGW249P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ENOXACIN

Official Name

English

NSC-629661

Code

English

PD 107779

Code

English

CI-919

Code

English

1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 1-ETHYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)

Common Name

English

AT-2266

Code

English

ENOXACIN [MI]

Common Name

English

1-ETHYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

Systematic Name

English

ENOXACIN [VANDF]

Common Name

English

PD-107779

Code

English

PENETREX

Brand Name

English

ENOXACIN [USAN]

Common Name

English

NSC-758416

Code

English

ENOXACIN [ORANGE BOOK]

Common Name

English

ENOXACIN [INN]

Common Name

English

ENOXACIN [WHO-DD]

Common Name

English

ENOXACIN [MART.]

Common Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/15/1459